To view this email as a web page, click here

Today's Rundown

Featured Story

AstraZeneca kick-starts new COVID variant-busting vaccine test

AstraZeneca has come under a lot of slack for its perceived poor communication and weaker results than its mRNA rivals, but the U.K. Big Pharma is still gunning in the COVID vaccine R&D game as its steps up to beat back new variants.

read more

Top Stories

Pfizer, CDC experts don't see eye to eye on COVID-19 boosters, threatening key revenue stream: analysts

Pfizer has predicted that a COVID-19 vaccine booster could be needed as soon as antibody blood concentration wanes to ensure the broad population can't carry the virus, Bernstein analysts wrote in a recent note. However, a key CDC panel doesn't appear to agree.

read more

Telehealth use falls 37% from pandemic highs, while demand for healthcare services projected to flatten: report

Future demand for healthcare services will be relatively flat to declining, with little to no effect from the COVID-19 pandemic, according to a new forecast report. At the same time, hospitals and health systems are facing increasing competition from consumer businesses such as Amazon and Walmart, retail behemoths that are rapidly expanding the supply of healthcare services.

read more

Biden administration 'absolutely supportive' of efforts to expand virtual care, HHS official says

President Joe Biden's top health official said the administration is "absolutely supportive" of efforts to expand telehealth flexibilities after the public health emergency expires. HHS also will ramp up oversight to ensure digital health and virtual care services are rolled out equitably across the country, HHS Secretary Xavier Becerra said.

read more

COVID-19 tracker: Mixing Pfizer, AZ shots produces strong response, study finds; Dr. Reddy's launches new drug

In a U.K. study, investigators found that mixing the COVID-19 vaccines from Pfizer and AstraZeneca produced a strong immune response. Plus, Dr. Reddy's Laboratories launched a new drug in India. And more.

read more